New England Journal of Medicine NOVEMBER 16, 2016

PIONEER AF-PCI: Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

C. Michael Gibson, Roxana Mehran, Christoph Bode, et al.

Bottom Line

In patients with atrial fibrillation undergoing PCI, two rivaroxaban-based antithrombotic strategies significantly reduced the risk of clinically significant bleeding compared to standard therapy with a vitamin K antagonist and dual antiplatelet therapy.

Key Findings

1. The primary safety outcome, clinically significant bleeding, occurred in 16.8% of patients in the low-dose rivaroxaban group (15 mg once daily plus a P2Y12 inhibitor) compared to 26.7% in the warfarin group (hazard ratio [HR] 0.59; P < 0.001).

2. The very-low-dose rivaroxaban group (2.5 mg twice daily plus DAPT) also showed a significantly lower rate of clinically significant bleeding at 18.0% (HR 0.63; P < 0.001 vs. warfarin).

3. Rates of major adverse cardiovascular events (death, MI, or stroke) were similar across all three treatment groups, although the study was not adequately powered to demonstrate non-inferiority for these efficacy endpoints.

4. A secondary analysis indicated that both rivaroxaban-based strategies were associated with lower rates of all-cause death or hospitalization for adverse events compared to the warfarin-based strategy.

Study Design

Design

RCT

Open-Label

Sample

2,124

Patients

Duration

12 mo

Median

Setting

Multicenter, international

Population Patients with non-valvular atrial fibrillation who underwent PCI with stent placement.

Intervention Two rivaroxaban-based regimens: (1) 15 mg once daily plus a P2Y12 inhibitor, or (2) 2.5 mg twice daily plus DAPT.

Comparator Standard triple therapy: dose-adjusted vitamin K antagonist plus DAPT (clopidogrel, ticagrelor, or prasugrel + aspirin).

Outcome Clinically significant bleeding (composite of TIMI major, TIMI minor, or bleeding requiring medical attention).

Study Limitations

• The study was an open-label trial, introducing potential reporting and ascertainment bias.

• The trial was primarily powered for safety rather than efficacy, limiting the ability to draw definitive conclusions regarding the prevention of ischemic events such as stent thrombosis, stroke, or MI.

• There was no direct comparison between the two rivaroxaban-based regimens.

• The duration of dual antiplatelet therapy (DAPT) was determined by physician discretion rather than randomization, which may introduce confounding in the duration-specific efficacy analysis.

• The study used reduced doses of rivaroxaban (15 mg and 2.5 mg BID), which differ from the standard doses used for stroke prevention in non-valvular atrial fibrillation (20 mg daily).

Clinical Significance

The results suggest that in patients with atrial fibrillation who require PCI, modifying the antithrombotic regimen by reducing the intensity of anticoagulation or simplifying the regimen to double therapy (rivaroxaban plus a P2Y12 inhibitor) can achieve meaningful reductions in bleeding without an apparent increase in serious ischemic complications, supporting a shift away from traditional triple therapy.

Historical Context

Prior to PIONEER AF-PCI, clinical guidelines for patients with atrial fibrillation requiring both anticoagulation and antiplatelet therapy after PCI were largely based on observational data or expert opinion. The trial followed the earlier open-label WOEST study, which suggested benefits of dual therapy over triple therapy, and provided the first randomized evidence for the use of a non-vitamin K antagonist oral anticoagulant (NOAC) in this challenging clinical scenario.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why do patients with atrial fibrillation who receive a coronary stent require both an anticoagulant and an antiplatelet agent, and what is the primary physiological risk of combining these therapies?

Key Response

Atrial fibrillation requires anticoagulation (like rivaroxaban) to prevent cardioembolic stroke by inhibiting the coagulation cascade, while coronary stents require antiplatelets (like P2Y12 inhibitors) to prevent platelet-rich stent thrombosis. The primary risk is a synergistic increase in bleeding, as both the primary and secondary pathways of hemostasis are inhibited simultaneously.

Resident

Based on the PIONEER AF-PCI trial, how does the 'dual-therapy' strategy (rivaroxaban + P2Y12 inhibitor) compare to the traditional 'triple therapy' (VKA + DAPT) in terms of safety and efficacy?

Key Response

The trial demonstrated that dual therapy significantly reduced the risk of clinically significant bleeding compared to triple therapy. However, the study was not sufficiently powered to definitively prove noninferiority regarding major adverse cardiovascular events (MACE) or stent thrombosis, necessitating a careful balance of bleeding vs. ischemic risk for the individual patient.

Fellow

The PIONEER AF-PCI trial used a 15 mg daily dose of rivaroxaban (or 10 mg for renal impairment) in its dual-therapy arm. Discuss the potential concerns regarding stroke prevention efficacy compared to the standard 20 mg dose validated in the ROCKET-AF trial.

Key Response

The 15 mg dose used in PIONEER was lower than the 20 mg dose proven for stroke prevention in the ROCKET-AF trial. While the PIONEER data showed no significant increase in stroke, the trial was underpowered for this endpoint. Fellows must consider whether reducing the dose for bleeding safety potentially compromises long-term protection against AF-related embolic events.

Attending

PIONEER AF-PCI was the first of several 'North Star' trials (including RE-DUAL PCI and AUGUSTUS) that shifted the paradigm away from triple therapy. In your practice, how do you integrate these findings for a patient with a high SYNTAX score but also a high HAS-BLED score?

Key Response

This requires a nuanced 'precision medicine' approach. While PIONEER supports early transition to dual therapy to reduce bleeding, a patient with high coronary complexity (high SYNTAX) might benefit from a limited period (e.g., 1-4 weeks) of triple therapy before transitioning to the PIONEER-style dual therapy to mitigate the early high risk of stent thrombosis.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of a composite primary safety endpoint that includes 'bleeding requiring medical attention' alongside TIMI major and minor bleeding in a non-blinded study design.

Key Response

Including 'bleeding requiring medical attention' increases the event rate and statistical power but introduces significant potential for ascertainment bias. In an open-label trial like PIONEER, patients and investigators aware of the treatment arm may have different thresholds for seeking or reporting medical attention for minor bleeding, potentially confounding the observed treatment effect.

Journal Editor

If you were reviewing the PIONEER AF-PCI manuscript, how would you address the discrepancy between the trial's power for its primary safety endpoint versus its secondary efficacy endpoint of MACE?

Key Response

A rigorous reviewer would highlight that while the safety results are robust, the efficacy conclusions are exploratory at best. The editor would ensure the authors do not overstate the 'equivalence' of ischemic protection, as the wide confidence intervals for MACE do not exclude a clinically relevant increase in thrombotic events compared to the standard of care.

Guideline Committee

How did the results of PIONEER AF-PCI influence the evolution of Class I recommendations in the ACC/AHA and ESC guidelines for the management of AF patients undergoing PCI?

Key Response

PIONEER AF-PCI provided the foundational evidence to move dual therapy from a 'consideration' to a preferred strategy. Current guidelines (e.g., 2023 AHA/ACC/ACCP/HRS) now give a Class 1 recommendation to DOAC-based dual therapy over VKA-based triple therapy to minimize bleeding, largely based on the safety profile established by PIONEER and subsequent trials.

Clinical Landscape

Noteworthy Related Trials

2013

WOEST Trial

n = 573 · Lancet

Tested

Clopidogrel monotherapy (dual therapy)

Population

Patients on oral anticoagulant therapy undergoing coronary stenting

Comparator

Clopidogrel plus aspirin (triple therapy)

Endpoint

Bleeding events

Key result: Dual therapy with clopidogrel and an oral anticoagulant was associated with significantly fewer bleeding complications compared to triple therapy without an increase in thrombotic events.

2017

RE-DUAL PCI Trial

n = 2,725 · NEJM

Tested

Dabigatran dual therapy

Population

Patients with nonvalvular atrial fibrillation who had undergone percutaneous coronary intervention

Comparator

Warfarin triple therapy

Endpoint

Major or clinically relevant non-major bleeding events

Key result: Dabigatran dual therapy resulted in significantly lower rates of bleeding than warfarin triple therapy and was noninferior for thromboembolic events.

2019

AUGUSTUS Trial

n = 4,614 · NEJM

Tested

Apixaban

Population

Patients with atrial fibrillation and acute coronary syndrome or undergoing PCI

Comparator

Vitamin K antagonist

Endpoint

Major or clinically relevant non-major bleeding

Key result: Apixaban resulted in fewer bleeding events and fewer hospitalizations than a vitamin K antagonist in patients with AF and ACS or PCI.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis